reports
- ING Helpdesk
Benelux Morning Notes
ABN AMRO: 1Q24 Preview. ABN AMRO: Press reports on sale of French Life Neuflize JV with AXA. Agfa-Geveart: A miss on every line. ASR: Dutch residential rental income risk insignificant. B&S Group: Solid start to the year, costs under control. DEME Group: 1Q solidifies FY24 revenue outlook. GBL: Accelerating its share buybacks. Just Eat Takeaway.com: M&A appetite. OCI: Improving 1Q24 performance at RemainCo assets, strategic update due on 2Q24
- Anthony Dick
- Michael Foundoukidis
- Anthony Dick
- Michael Foundoukidis
- Gerardo Ibanez
- Steven Boumans
Care Property Invest : Care Property Invest to Outperform: 3 reasons w...
>Healthcare real estate is not out of the woods yet, but we see some green shoots - We have been cautious on the healthcare real estate stocks for over a year now, after the problems with operators appeared to be more structural and broad based than idiosyncratic. We are not out of the woods yet. However, there are some silver linings for the segment, where nursing home operator health is improving. Not enough to become bullish on the whole segment, but enough to upgr...
IBA : 2024 AGM - Convening Notice
IBA : 2024 AGM - Convening Notice Cher Actionnaire, Nous avons l’honneur de vous convoquer à l’Assemblée Générale Ordinaire (l’« AGO ») des actionnaires d’IBA qui se tiendra le mercredi 12 juin 2024 à 10h00, pour délibérer sur l’ordre du jour détaillé ci-joint. L’AGO sera organisée en présentiel au siège de la Société. Une retransmission est également prévue en ligne, accessible sur inscription préalable, mais il ne sera pas possible de voter en ligne. Il s’agit d’une simple retransmission. Les actionnaires sont fortement encouragés à voter préalablement à l’AGO, dans les délais légau...
UCB SA: 2 directors
Two Directors at UCB SA sold/bought 1,385 shares at 128.760USD. The significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Sharad Kumar S.P
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Wim Hoste
Solvay Model update post 1Q, reconfirming our BUY rating
We upped our FY24 adjusted EBITDA forecast by 2% following the better than expected 1Q24 results. After the recent spun off of Syensqo, Solvay is a base chemicals group with leading market and technology positions in the vast majority of its businesses. The company will be managed with a conservative financial approach, favouring dividends over aggressive growth and operating with a solid balance sheet (1.4x leverage). The stable to growing dividend flow implies a solid 7% dividend yield. Other ...
- Wim Hoste
Solvay Conference call feedback
Below are the highlights from the conference call. 1Q underlying EBITDA dropped by 13.6% organically to 265m which was 13% better than our forecast and 12% above CSS. Solvay reiterated its FY uEBITDA guidance which calls for a 10-20% organic decline vs the restated 2023 base. After the recent spun off of Syensqo, Solvay is a base chemicals group with leading market and technology positions in the vast majority of its businesses. The company will be managed with a conservative financial approach...
- Martin Marandon-Carlhian
- Stephane Houri
FME FRESENIUS MEDICAL CARE AG & CO. KGAA
RCO REMY COINTREAU SA
LONN LONZA GROUP AG
EN BOUYGUES SA
ADEN ADECCO GROUP AG
SCR SCOR SE
ZAL ZALANDO SE
GEBN GEBERIT AG
HEI HEIDELBERGCEMENT AG
SOLB SOLVAY SA
COLO B COLOPLAST A/S CLASS B
BP. BP P.L.C.
SHL SIEMENS HEALTHINEERS AG
UN0 UNIPER SE
- Martin Marandon-Carlhian
- Stephane Houri
INFINEON INFINEON TECHNOLOGIES AG
FME FRESENIUS MEDICAL CARE AG & CO. KGAA
RCO REMY COINTREAU SA
LONN LONZA GROUP AG
EN BOUYGUES SA
ADEN ADECCO GROUP AG
SCR SCOR SE
ZAL ZALANDO SE
GEBN GEBERIT AG
HEI HEIDELBERGCEMENT AG
SOLB SOLVAY SA
COLO B COLOPLAST A/S CLASS B
BP. BP P.L.C.
SHL SIEMENS HEALTHINEERS AG
UN0 UNIPER SE
- ING Helpdesk
- Hilde Van Boxstael
- Sharad Kumar S.P
- Wim Hoste
- Wim Lewi
- Stefano Toffano
Solvay : A solid quarter despite the large net pricing headwinds
>Pressure on underlying EBITDA less than expected - A good first set of results for the new Solvay, with Q1 24 group revenues of € 1,201m (+6% vs ccs) reflecting -11.9% yoy organic growth mainly as a consequence of lower prices (-14.5% yoy), partially offset by higher volumes (+2.5% yoy). Q1 24 underlying EBITDA came in much stronger than expected at € 265m (-27.2% yoy, -13.6% organically given the exit from the thermal insulation and energy third parties operations) ...
- Wim Hoste
Solvay FIRST LOOK: 1Q underlying EBITDA beat, FY guidance maintained
1Q underlying EBITDA dropped by 13.6% organically to 265m which was 13% better than our forecast and 12% above CSS. Solvay reiterated its FY uEBITDA guidance which calls for a 10-20% organic decline vs the restated 2023 base. After the recent spun off of Syensqo, Solvay is a base chemicals group with leading market and technology positions in the vast majority of its businesses. The company will be managed with a conservative financial approach, favouring dividends over aggressive growth and op...
ABN AMRO completes EUR 500 million share buyback programme of 15 Febru...
ABN AMRO completes EUR 500 million share buyback programme of 15 February 2024 ABN AMRO completes EUR 500 million share buyback programme of 15 February 2024 ABN AMRO today announced that it has completed its EUR 500 million share buyback programme which started on 15 February 2024. Under the share buyback programme a total of 32,526,813 ordinary shares and depository receipts were purchased, representing 3.76% of issued shares, at an average price of EUR 15.37. ABN AMRO intends to cancel the repurchased ordinary shares and corresponding depository receipts in due course. NLFI as a...
Solvay first quarter 2024 results
Solvay first quarter 2024 results Strong FCF supported by resilient EBITDA and discipline on costs and capex Brussels, May 7, 2024 – 7:00 am CEST - regulated information Highlights Net sales for Q1 2024 at €1,201 million were down -11.9% organically versus Q1 2023, with positive volume impact, for the first time in seven quarters, in both Basic and Performance Chemicals segments. Prices decreased, mostly reflecting the lower energy and raw material costs.Underlying EBITDA of €265 million for the first quarter was -13.6% lower organically compared to a high Q1 2023, with negative Net ...
Résultats du premier trimestre 2024
Résultats du premier trimestre 2024 Information réglementée Un FCF solide soutenu par un EBITDA résilient et la gestion maîtrisée des coûts et des investissements Bruxelles, le 7 mai 2024 à 7h00 CEST - information réglementée Faits marquants Le chiffre d'affaires net du T1 2024 s’élève à €1 201 millions, en baisse organique de -11,9% par rapport au T1 2023, avec un impact positif des volumes pour la première fois en sept trimestres, visible à la fois dans les segments Basic Chemicals et Performance Chemicals. Les prix diminuent, reflétant principalement la baisse des coûts de l'énergie...
Resultaten Solvay van het eerste kwartaal 2024
Resultaten Solvay van het eerste kwartaal 2024 Gereglementeerde informatie Sterke vrije kasstroom ondersteund door veerkrachtige EBITDA en beheersing van kosten en investeringen Brussel, 7 mei 2024, om 7u00 CEST - gereglementeerde informatie Hoogtepunten De netto-omzet voor Kw1 2024 van €1 201 miljoen daalde op organische basis met -11,9% ten opzichte van Kw1 2023, met een positieve volume-impact, voor het eerst in zeven kwartalen, in zowel de segmenten Basic Chemicals als Performance Chemicals. De prijzen daalden, vooral door lagere energie- en grondstofkosten.De onderliggende EBITDA...
- Frank Claassen
Solvay - Resilience and return of volume growth
• Q1-24 EBITDA was more than 10% above our and consensus estimates, supported by the return of positive volume growth. • This confirms our view that Solvay is resilient, also due to its strong cost and capex discipline.• Valuation multiples remain very attractive for a 20% ROCE business. We stick our Buy and TP of EUR 36, based on our 2025E SOTP.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.